Standard IS regimens: CNI is still the cornerstone

R. Vos (Leuven, Belgium)

Source: ERS Course 2016
Number: 15

PDF journal article, handout or slidesSlide presentationWebcastMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Vos (Leuven, Belgium). Standard IS regimens: CNI is still the cornerstone. ERS Course 2016

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Four-month regimens: are they feasible?
Source: International Congress 2015 – Tuberculosis: short-course chemotherapy
Year: 2015

First-line therapy
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009

Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016

Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation?
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018

Combination therapy in the era of immunotherapy
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019

Comparison of post renal transplant tuberculosis cases receiving conventional immunosupressive therapy and mycophenolat mofetil (MMF) and/or tacrolimus (TAC)
Source: Eur Respir J 2003; 22: Suppl. 45, 157s
Year: 2003

Glucocorticosteroid treatment in sarcoidosis: comparison of regimens
Source: Eur Respir J 2003; 22: Suppl. 45, 234s
Year: 2003

Myrin P implementation in the chemotherapy standard regimens
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001

Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021

Second- and third-line therapies: what are the best options?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007

Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants
Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis
Year: 2021

Patient education via tablet-pc vs. conventional to improve compliance with immunosuppressive drug regimen after lung transplantation - a randomized controlled trial
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013

Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012